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RESUMEN
Objetivo: La presente investigación tuvo como objetivo desarrollar y optimizar las microesponjas de 
nitrato de miconazol para el tratamiento de la dermatitis del pañal para un efecto terapéutico mejorado.
Material y métodos: Las microesponjas fueron desarrollados por emulsión técnica de difusión del di-
solvente usando un diseño factorial 23. Las microesponjas fabricadas han sido optimizadas con el fin de 
analizar los efectos de las variables independientes sobre la eficacia de encapsulación, tamaño de partí-
cula, la topografía de la superficie y en la liberación de fármaco in vitro. A continuación, la formulación 
optimizada se incorporo en un gel y se evaluó.
Resultados: Se encontró que el tamaño de partículas de todas las formulaciones fue uniforme y la mi-
croscopía electrónica de barrido (SEM) indicó forma esférica y de naturaleza porosa de las microespon-
jas. En la liberación del fármaco, estudios in vitro de todas las formulaciones, revelaron la velocidad 
de liberación dentro de un intervalo de 67±0,09% a 80,6±0,68% al cabo de 12 horas. Con esta base, La 
formulación F8 se seleccionó y se incorporó en el gel (CF8) en el que se evaluó el pH, viscosidad, capa-
cidad de extensión, estudios de difusión in vitro del fármaco, estudios in vitro anti hongos y estudios 
de estabilidad.
Conclusión: El gel a base de microesponja formulado de nitrato de miconazol sería un sustituto adecua-
do al tratamiento tradicional para la curación fiable y económica de la dermatitis del pañal.
Palabras clave: Microsponge, Liberación de fármacos, Eudragit RS100, Nitrato de miconazol, Dermatitis 
del pañal.
ABSTRACT
Aim: The current investigation was aimed to develop and optimize the microsponges of miconazole 
nitrate for treatment of diaper dermatitis for enhanced therapeutic effect.
Material and Methods: Microsponges were developed by emulsion solvent diffusion technique using 23 
factorial design. Fabricated microsponges were optimized in order to analyze the effects of independent 
variables on the encapsulation efficiency, particle size, surface topography and in vitro drug release. The 
optimized formulation was then incorporated into the gel and evaluated.
Results: Particle size of all formulations was found to be uniform and scanning electron microscopy 
(SEM) indicates spherical shape and porous nature of microsponges. In vitro drug release studies of all 
formulations revealed the release rate within the range of 67%±0.09 to 80.6%± 0.68 at the end of 12 hours. 
On its basis, formulation F8 was selected and incorporated into the gel (CF8) which was evaluated for 
pH, viscosity, spreadability, in vitro drug diffusion studies, in vitro anti fungal studies and stability stud-
ies.
Conclusion: The formulated microsponge-based gel of miconazole nitrate would be a capable substitute 
to traditional treatment for reliable and economical cure of diaper dermatitis.
Key Words: Microsponge delivery system, Eudragit RS100, Miconazole Nitrate, Topical Drug Delivery, 
yeast diaper dermatitis.
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INTRODUCTION
Numerous drug delivery systems have been developed for 
the drugs as transdermal delivery system (TDS) using the 
skin as doorway for entrance. Despite of improved efficacy 
of drug delivery, TDS is not realistic for the delivery of ac-
tives whose final target is skin itself [1]. Drug controlled re-
lease onto epidermis asserts that the drug remains primar-
ily localized and does not enter the systemic circulation in 
significant amounts. Many conventional formulations such 
as ointments, gels etc. require high concentrations of drug 
for an effective therapy, which results in great number of 
side effects. Thus, it becomes essential to boost the amount 
of time that a drug remains on skin surface or epidermis 
and simultaneously decreasing its transdermal penetration 
into the body[2].
The microsponge delivery system (MDS) satisfies these 
constraints. MDS is a distinctive technology comprises of 
10-100um diameter drug loaded microporous beads which 
aids in controlled delivery of drugs [3]. Rubbing, moisture, 
pH, friction, or ambient skin temperature are triggering 
factors for the controlled release of drug from microspong-
es by diffusion through skin. Microsponges has the facility 
to load wide range of active ingredients like essential oils, 
fragrances, anti infectives, antifungals, etc [4].
Topical fungal infections are among the most common skin 
disorders and occur in both healthy and immune compro-
mised persons. Dermatophytes, yeasts and non-dermato-
phyte molds cause them. For the new borns and toddlers, 
diaper rash or yeast diaper dermatitis is a widespread 
problem which develops on the bums[5]. Yeast is a fungus 
that lives on the skin and in the intestines, and when it gets 
a warm and moist environment in the diaper area, it causes 
rash. To treat these rashes, antifungal drugs loaded creams 
and ointments are prescribed which have problems of con-
ventional topical drug delivery system like high dose for 
effective therapy and high dosing frequency [6].
Miconazole nitrate provides relief from the symptoms of 
diaper dermatitis. Infants having more than 4 weeks of age 
are given maximum treatment up to 7 days followed by ap-
plication of lubricants or emollients as protective layer [7]. 
Miconazole Nitrate inhibits ergosterol synthesis that results 
in increased cellular permeability, causing leakage of cel-
lular contents. Other antifungal effects of azole compounds 
have been proposed and include inhibition of endogenous 
respiration, interaction with membrane phospholipids, and 
inhibition of yeast transformation to mycelial forms [8].
Thus, the aim of present investigation is to develop micon-
azole nitrate loaded microsponges delivery system with 
an aim to reduce the dose and dosing frequency associ-
ated with conventional topical drug delivery system and 
achieve the therapeutic objective. The fabricated micro-
sponges will be characterized with respect to particle size, 
surface morphology, drug entrapment efficiency, in vitro 
diffusion studies, in vitro antifungal studies, release kinet-
ics and stability studies.
MATERIAL AND METHODS
Materials
Miconazole nitrate was a kind gift from Basic Pharma Life 
Sciences Pvt. Ltd., Gujarat. Eudragit RS 100, Polyvinyl Al-
cohol, Dichloromethane and ethanol was purchased from 
S.D fine Chem Ltd. All solvents are of analytical grade.
Methodology
Statistical Experimental Design for formulation Optimization
A full factorial design consists of two or more factors, each 
with discrete possible values or «levels», and whose experi-
mental units take on all possible combinations of these lev-
els across all such factors. A common experimental design 
is one with all input factors set at two levels each. These 
levels are called `high’ and `low’ or `1’ and `0’, respectively. 
A design with all possible high/low combinations of all the 
input factors is called a full factorial design in two levels 
[9, 10]. If there are k factors, each at 2 levels, a full factorial 
design has 2k Factorial design. 23 imply 8 runs as shown in 
Table 1.
Preparation of Miconazole nitrate loaded Microsponges
Microsponges were prepared by quasi emulsion solvent 
diffusion as shown in Table 2. The required amount of 
miconazole nitrate and Eudragit RS100 polymer were 
weighed accurately and dissolved in 5ml of Dichlorometh-
ane: Ethanol (1:1) under sonication. Polyvinyl alcohol was 
weighed accurately and dissolved in distilled water at 60ºC. 
The surfactant was allowed to cool to room temperature. 
The internal phase containing miconazole nitrate and eu-
dragit RS100 was added drop wise with the aid of syringe 
with stirring at 800 rpm until the complete diffusion of the 
external phase i.e. about 8 h. After complete diffusion of the 
external phase, the microsponges were filtered and dried 
overnight at room temperature as shown in Figure 1. [11, 12]
CHARACTERIZATION OF MICONAZOLE NITRATE 
MICROSPONGES
Particle Size and Size Distribution Analysis
The particle size was determined using an optical micro-
scope. The microscope was fitted with a stage micrometer 
to calibrate the eyepiece micrometer [13]. The values were 
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given for the formulations in the form of mean particle size 
range.
One division of stage micrometer = 0.01 mm = 10 μm.
C = SM × 10/EM
Where,
C = correction factor;
SM = reading of stage micrometer which coincides with 
reading of eyepiece micrometer (EM).
The particle diameter of around 100 particles was meas-
ured.
The average particle size was determined using the follow-
ing formula:
Dmean = Σnd/ Σn
Where, n = number of microsponges observed and
d = mean size range.
Each formulation was observed three times and average of 
three trials was calculated.
Shape and Surface Morphology of Microsponges
Shape and surface morphology of miconazole microspong-
es was visualized by scanning electron microscopy (LEO-
430 Cambridge and U.K). Samples were prepared by light-
ly sprinkling microsponges on a double adhesive tape, on 
an aluminum stub. The stubs were then coated with gold 
to a thickness of 200 to 500 A0 under an argon atmosphere 
using gold sputter module in a high vacuum evaporator [14]. 
The samples were then randomly scanned and photomicro-
graphs taken at different magnifications with SEM.
Drug entrapment efficiency
The entrapment efficiency and drug loaded microsponges 
were estimated by dissolving 50 mg of microspheres in 0.01 
N HCl. The samples were analyzed using UV-Visible spec-
trophotometer (Shimadzu UV 1800) at a wavelength 272 
nm. Entrapment efficiency was calculated in triplicate us-
ing the following equations [15]:
Production Yield
For calculating production yield, theoretical mass was cal-
culated initially by taking the weight of excipients. The pro-
duction yield of the microsponges was determined accu-
rately by calculating the initial weight of the excipients and 
the final weight of the formulation obtained [16]. Production 
Yield was calculated in triplicate using the following equa-
tion.
In Vitro Drug Release Studies
The drug release studies of miconazole nitrate loaded mi-
crosponges were carried out using basket dissolution ap-
paratus (USP Type I apparatus). 900ml of fresh phosphate 
buffer saline (PBS pH 5.5) was used for the release studies. 
The temperature of the dissolution medium was controlled 
at 32±1°C with 150 rpm rotation speed. Microsponges 
equivalent to 50 mg of miconazole nitrate were weighed. At 
fixed time intervals, aliquots of samples were withdrawn 
and replaced by an equal volume of fresh dissolution me-
dium to maintain the sink conditions. After suitable dilu-
tion, the samples were analyzed spectrophotometrically at 
272 nm (Shimadzu UV-1208) against blank.
The release studies were carried out for 12 h. [17]. Based on 
the evaluation characteristics, the optimized formulation 
of each polymer was incorporated into suitable gel bases 
and evaluated further. All the readings were repeated three 
times.
Preparation of Miconazole Nitrate Microsponges load-
ed Topical gel
Gel formulation was developed using carbopol® 934 as 
gelling agent. The accurately weight quantity of carbopol® 
934 (1%w/v) was dispersed in beakers containing adequate 
amount of water under constant stirring and allowed to hy-
drate for 24 h at room temperature. Later, glycerine and op-
timized microsponges formulation containing miconazole 
nitrate was incorporated into the carbopol gel with the help 
of mechanical stirrer at 25 rpm. Then, water was added to 
gel under constant stirring. The dispersion was neutralized 
using triethanolamine (0.5% w/w) [18]. The gel was allowed 
to stand overnight to remove entrapped air. The formula-
tion was transferred to a suitable container and stored for 
further studies.
EVALUATION OF MICROSPONGES LOADED GEL 
FORMULATIONS:
The prepared gels were evaluated for different parameters 
such as pH, appearance, viscosity, spreadability, drug con-
tent and drug release, in vitro antifungal activity and stabil-
ity studies with the aim of checking the efficacy of micro-
sponges loaded gel formulations.
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Appearance
The prepared gel bases were inspected visually for clarity, 
colour and presence of any particles. Transparent gel was 
found in microsponges loaded carbopol gel.
pH
1g of microsponges loaded gel formulation was dissolved 
in 100 ml water and the pH was determined with the help 
of digital pH meter [19]. All the gels were tested for pH three 
times and average of three determinations was calculated.
Rheological Studies
Spreadability:
The spreadability studies of microsponges loaded gel for-
mulations were carried out by keeping gel between two 
horizontal glass slides of standard dimension. 100 g weight 
was placed on top of the two slides so that the formulation 
gets uniformly spread. The weight was removed and ex-
cess formulation was scraped out [20]. The experiment was 
carried out in triplicate.
S = m. l/ t
Where,
m = weight kept on the upper slide
l = length of glass slide
t= time taken in seconds.
Viscosity:
Viscosity of microsponges loaded gel formulation was de-
termined using Brookfield viscometer with spindle No. 6 at 
10 rpm at temperature 37±0.5°C [21].
Drug Content
One gram of gel formulation containing drug equivalent to 
10 mg of miconazole nitrate was extracted and the volume 
was made up to 50 ml with ethanol. The resulting solution 
was filtered. Suitable dilutions of the filtrate were prepared 
with filtered phosphate buffer pH 5.5 and absorbance was 
measured at 272 nm using UV spectrophotometer (Shimad-
zu UV-1208). All readings were taken in triplicate and aver-
age was calculated [22].
In vitro Drug Diffusion Studies
In vitro diffusion study was conducted using Keshary-
Chien (K-C) cell with an effective diffusion area of 2.0 cm2 
and a cell volume of 25 mL. Phosphate Buffer Saline (pH 
5.5) was used as dissolution medium, and system was ther-
moregulated with a water jacket at 37±1 oC under constant 
stirring. The cellophane membrane (0.45 μm) previously 
soaked overnight in dissolution medium was mounted 
onto K-C cell. Microsponges loaded gel formulation was 
assessed for diffusion study. 1ml of sample aliquots were 
withdrawn at predetermined time intervals and subse-
quently replenished with an equal amount of phosphate 
buffer. The samples were filtered, diluted and analyzed 
using UV spectrophotometer at 272nm against blank [23]. 
The release studies were carried out for 10 h and the re-
lease data were analyzed by means of diverse mathemati-
cal models to know release kinetics.
In vitro Antifungal Study
For antifungal studies, sabouraud’s dextrose agar was uti-
lized. The media was taken in a 250 ml conical flask and 
dissolved in 100 ml of distilled water. The pH was adjusted 
to 5.6 ± 0.2. The medium was sterilized in an autoclave at 15 
lbs (121oC) for 15 min. After sterilization, the medium was 
allowed to cool down at room temperature and poured into 
presterilized petridishes inside a laminar airflow unit with 
layer of uniform thickness. Medium filled petridishes were 
kept in laminar airflow unit for solidification, after which 
a loop of diluted suspension culture (Candida albicans) 
in nutrient broth was added on to the surface of solidified 
agar and was spread uniformly with the help of spreader. 
Culture was then stabilized, subsequent to which 6mm 
diameter cups were punched using sterile cork borer and 
scraped out from the petridish [24].
Microsponges loaded gel formulation (equivalent to 0.25% 
miconazole nitrate) and marketed formulation of micona-
zole nitrate was fed into the cup separately. The petridishes 
were then incubated for 24 h at 37 °C. After incubation the 
zone of inhibition was measured.
Release Kinetics
Data obtained from release studies of gels was subjected to 
kinetic treatment such as zero order drug release, first or-
der drug release, Higuchi’s square root plot and Korsmey-
er-Peppas model to obtain the order of release and release 
mechanism [25].
Stability studies
Optimized gel formulation was subjected to stability test-
ing as per ICH guidelines. Gel was filled in clean, glass vi-
als and various replicates were kept at 5oC±2, 25oC±2 and 
40oC/75% RH in a humidity chamber for a period of 60 
days [26]. Gel was assessed for change in appearance and 
drug content at an interval of 7, 15, 30, 45 and 60 days.
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RESULT AND DISCUSSION
Miconazole nitrate loaded microsponges were successfully 
formulated using quasi-emulsion solvent diffusion tech-
nique. The technique used for the fabrication is very sim-
ple, replicable and quick [11]. Eudragit RS 100 and polyvinyl 
alcohol were used as microsponges forming polymer and 
surfactant respectively. 23 factorial design was applied for 
the optimization of formulation parameters and process 
variables. Prior to application of factorial design, a broad 
range optimization was carried out so as to widely select 
the parameters for further experimentation.
Different concentrations of polymer viz. 100 to 400mg were 
chosen for its optimization and keeping other parameters 
constant like surfactant 0.75%w/v and 800 rpm stirring 
speed. Out of all concentration, 300mg polymeric concen-
tration showed spherical porous microsponges with good 
entrapment efficiency 79.6%±0.23 and 66.7±0.17 μm particle 
size as shown in Figure 2. Thus, it was selected for further 
optimization. The type and concentration of surfactant has 
a key role to play in the preparation of microsponges. By 
keeping other parameters constant (polymer 300mg and 
stirring speed 800rpm) and varying the concentration of 
surfactant from 0.5% to 1.5 % w/v, the particle size also 
varied from 66.43μm to 92.54 μm. The minimum concen-
tration of surfactant required to bring about the formation 
of uniform microsponges was found to be 0.75% w/v as 
illustrated in Figure 3. Stirring speed also played a crucial 
role in the formation of microsponges with reduced par-
ticle size. Likewise varying stirring speed was selected 
viz. 100, 400, 800, 1200 rpm and keeping other parameters 
(polymer 300mg and surfactant 0.75%w/v) constant. The 
results showed formulation prepared with 800 rpm stirring 
speed showed smallest particle size and good entrapment 
efficiency 65.25%±0.34 as shown in Figure 4. Thus, 300mg 
polymer concentration, 0.75%w/v surfactant concentration 
and 800rpm stirring speed were selected for the further op-
timization with the aid of factorial design.
The 23 factorial design enabled the selection of optimized 
formulation. Three factors (viz. polymer concentration, 
surfactant concentration and stirring speed) and two levels 
(low (0) & high (1)) were selected as shown in Table 1, as 
these are most important factors (independent variables), 
which can affect particle size, entrapment efficiency and in 
vitro drug release (dependent variables).
The mean particle size of microsponges was found to be 
in the range of 10.32μm±0.32 to 98.45±0.71μm. Visual as-
sessment of all formulations was done using optical mi-
croscope, which clearly indicates that as the particle size 
increased with increase in the concentration of polymer. It 
may be due to additional presence of polymer in solution, 
which in turns increases, the wall thickness resulting larger 
microsponges. Furthermore, increasing amount of poly-
mer causes increase in apparent viscosity at augmented 
polymeric concentrations. Consecutively, bigger emulsion 
droplets formed and size of microsponges increases. For-
mulation F8 showed minimum particle size 66.42± 0.31 μm 
which may be due to optimum concentration of polymer 
and surfactant. High stirring speed results in smallest par-
ticle size that is stabilized by surfactant.
For morphology and surface topography investigation, 
fabricated microsponges were subjected to SEM analysis. 
The captured SEM image of microsponges is shown in 
Figure 5. It was observed that the obtained microsponges 
were substantially porous, predominantly spherical and 
have uniform outline. Highly Porous morphology may be 
attributed due to diffusion of solvent from microsponges 
surface. The findings of entrapment efficiency were found 
to be in the range of 50.18%± 0.23 to 83.5% ± 0.91 for all 
the eight formulations. Likewise, entrapment efficiency in-
creases due to increase in polymer concentration. Highest 
entrapment was found to be 83.5% ± 0.91 which was shown 
by F8 formulation due to optimum polymer and surfactant 
concentration.
The production yield of all eight formulations ranged from 
78.66%± 0.10 to 87.5%± 0.91. The polymer concentration 
was found to have a significant effect on production yield. 
Figure 6. High polymer concentration reduces the dichlo-
romethane diffusion rate from viscous polymeric solution 
to aqueous phase that provides more time for droplet for-
mation and thus yield improves.
In vitro drug release studies were successfully done using 
basket type apparatus and the cumulative percentage drug 
release at the end of 12 hrs was noted to be 67.5%±0.09 to 
80.6%±0.68. Maximum release was shown by F8 formula-
tion i.e. 80.6%±0.68. The cumulative release profiles dis-
played a bi-phasic release with an initial burst effect i.e. 
3.8±0.12 in 0.25 h to 26.7±0.29 in 2h followed by sustained 
release as shown in Figure 7. Drug release decreases with 
an increase in polymer concentration.
On the basis of factorial design, miconazole nitrate mi-
crosponge formulation F8 was found to be optimized for 
further gel formulation. Gel was successfully formulated 
using 1%w/v carbopol® 934 as gelling agent, glycerin as 
smoothening agent and triethanolamine as cross-linking 
agent.
Gel was found transparent, uniform with no presence of air 
molecules. The pH values of all formulations were found in 
the range of 5.7–5.8, which are supposed to be suitable to 
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pass up threat of nuisance on application to skin. The out-
come of spreadability illustrated that formulated gels get 
easily spread on applying small amount of shear. Spread-
ability of gel containing microsponges was found to be 
2.54g.cm/s; signifying that spreadability of drug loaded 
microsponge gel was good. The viscosity of prepared mi-
conazole nitrate loaded microsponge gel was found to be 
38,200 cPs. The viscosity was found to be dependent on 
polymeric content of formulation. In vitro diffusion studies 
of microsponges loaded gel was conducted in phosphate 
buffer saline (pH 6.8) using K-C cell upto 12 h. sAccording 
to the results obtained, it was noted that, the cumulative 
drug diffused at the end of 10 hrs was 82.78%± 0.91. Results 
of cumulative drug diffused were subjected to release ki-
netics models that portrayed that the formulation follows 
higuchi release (r2=0.982). To confirm the exact mechanism 
of drug release, the data were fitted according to Korse-
meyer-Peppas equation. The value of N = 0.86 which shows 
non-fickian in nature as shown in Table 3. Optimized mi-
crosponges formulation (F8) loaded carbopol gel showed 
maximum zone of inhibition of 17mm as compared to mar-
keted formulation (15mm) of miconazole nitrate.
Stability studies results of optimized microsponges formu-
lation loaded carbopol gel displayed no significant changes 
in the physical appearance and drug content which clearly 
suggest that the formulations are stable at 5°C and 25°C. 
However, some drug degradation was observed at 40° C/ 
75 % RH as tabulated in Table 4.
CONCLUSION
For the existing era and future prospects, sustained drug 
delivery by means of polymer based systems has been rec-
ommended to exist owing to frequent probable benefits for 
technical and cost effective grounds. The notion behind 
the development of polymer based microsponge delivery 
system was to release the active in a recurrent approach 
for wide time period to cut the dosing frequency and to 
improve bioavailability. The technique executed was emul-
sion solvent diffusion that was found to be simple, repro-
ducible and rapid. Fabricated microsponges were spherical 
in shape and have porous texture. Microsponge based gel 
reflected Higuchi release kinetics and controlled by non-
fickian release mechanism. Thus, gel comprising micro-
sponges was found as an potential drug delivery system 
presenting prolonged release of miconazole nitrate in the 
treatment of diaper dermatitis.
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Table 1: 23 Factorial Design for Miconazole nitrate microsponges formulation
S. No Factors
Levels
0 1
A Eudragit RS 100 (mg) 300 350
B Polyvinyl Alcohol (%w/v) 0.75% 1.0%
C Stirring Speed (rpm) 600 800
Table 2: Formulation table for development of miconazole nitrate microsponges
Formulation Code (A) (B) (C)
F1 0 (300) 0 (0.75%) 0 (600)
F2 0 (300) 1 (1.0%) 1 (800)
F3 1 (350) 0 (0.75%) 0 (600)
F4 1 (350) 1 (1.0%) 1 (800)
F5 1 (350) 0 (0.75%) 1 (800)
F6 0 (300) 1 (1.0%) 0 (600)
F7 1 (350) 1 (1.0%) 0 (600)
F8 0 (300) 0 (0.75%) 1 (800)
Table 3: Release Kinetics Assessment of Optimised Miconazole Nitrate Loaded Microsponges Carbopol Gel
Formulation code
Zero-order First order Higuchi type Korsemeyer-peppas
r2 k r2 k r2 k r2 N
CF8 0.9568 5.26 0.978 0.026 0.982 16.05 0.631 0.86
Table 4. Stability Studies data for Optimised Miconazole Nitrate Loaded Microsponges Carbopol Gel
S.No.
Time
(Days)
5o ± 2 oC 25o ±2oC 40oC/75%RH
Physical 
Appearance
Drug 
Content
Physical 
Appearance
Drug 
Content
Physical 
Appearance
Drug 
Content
1. 7 +++ 99.95 ± 0.12 +++ 99.93 ± 0.03 +++ 99.90 ± 0.17
2. 15 +++ 99.92 ± 0.16 +++ 99.88 ± 0.65 ++ 99.67 ± 0.83
3. 30 +++ 99.87 ± 0.05 +++ 99.84 ± 0.26 ++ 99.27 ± 0.28
4. 45 +++ 99.80 ± 0.56 ++ 99.79 ± 0.16 + 98.85 ± 0.39
5. 60 ++ 99.75 ± 0.23 ++ 99.70 ± 0.28 + 98.50 ± 0.12
(+++ indicates no change, ++ indicates slight change, + indicates significant change)
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Figure 1. Schematic Diagram illustrationg formation of Microsponges using 
Quasi-emulsion diffusion technique
Figure 2: Optimization of polymer Concentration for microsponges formulation
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Figure 3: Optimization of Surfactant Concentration for microsponges formulation
Figure 4: Optimization of Stirring speed concentration for microsponges formulation
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Figure 5: SEM Photomicrograph of Miconazole Nitrate Loaded Microsponges
Figure 6: Drug Entrapment Efficiency and production Yield of All microsponges formulations
Figure 7:Cumulative In vitro drug release profiles of all eght microsponges formulations
